– Reuters Citing Downdetector
Mizuho Initiates Coverage On Abiomed with Buy Rating, Announces Price Target of $300
Mizuho analyst Anthony Petrone initiates coverage on Abiomed (NASDAQ:ABMD) with a Buy rating and announces Price Target of $300.